Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 2,155 shares of the business’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $175.36, for a total value of $377,900.80. Following the completion of the sale, the executive vice president now directly owns 48,907 shares in the company, valued at $8,576,331.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
VRTX stock opened at $175.23 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1-year low of $136.50 and a 1-year high of $194.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.71 and a quick ratio of 3.59. The firm has a market capitalization of $44.29 billion, a PE ratio of 219.04, a price-to-earnings-growth ratio of 1.72 and a beta of 1.61.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.07. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. The firm had revenue of $784.54 million during the quarter, compared to analysts’ expectations of $782.95 million. During the same quarter in the previous year, the business earned $0.53 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 2.55 EPS for the current fiscal year.
VRTX has been the topic of several analyst reports. Jefferies Financial Group boosted their target price on Vertex Pharmaceuticals to $210.00 and gave the stock a “buy” rating in a report on Monday, July 16th. BMO Capital Markets boosted their target price on Vertex Pharmaceuticals to $204.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Piper Jaffray Companies boosted their target price on Vertex Pharmaceuticals to $230.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. Oppenheimer boosted their target price on Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Finally, Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $207.00 to $211.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. Three equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and an average target price of $202.14.
Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Vertex Pharmaceuticals by 42.1% in the second quarter. Renaissance Technologies LLC now owns 4,050,617 shares of the pharmaceutical company’s stock worth $688,443,000 after purchasing an additional 1,199,700 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Vertex Pharmaceuticals by 3.1% in the third quarter. Wells Fargo & Company MN now owns 2,151,713 shares of the pharmaceutical company’s stock worth $414,720,000 after purchasing an additional 64,205 shares during the last quarter. Fred Alger Management Inc. increased its position in Vertex Pharmaceuticals by 10.8% during the second quarter. Fred Alger Management Inc. now owns 1,960,493 shares of the pharmaceutical company’s stock valued at $333,205,000 after acquiring an additional 191,072 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Vertex Pharmaceuticals by 10.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,839,645 shares of the pharmaceutical company’s stock valued at $354,574,000 after acquiring an additional 176,093 shares during the last quarter. Finally, Putnam Investments LLC increased its position in Vertex Pharmaceuticals by 2.3% during the second quarter. Putnam Investments LLC now owns 1,751,760 shares of the pharmaceutical company’s stock valued at $297,730,000 after acquiring an additional 39,166 shares during the last quarter. Hedge funds and other institutional investors own 93.51% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Stuart A. Arbuckle Sells 2,155 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/07/stuart-a-arbuckle-sells-2155-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
See Also: Risk Tolerance
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.